{"id":4919,"date":"2024-05-29T10:31:01","date_gmt":"2024-05-29T08:31:01","guid":{"rendered":"https:\/\/studienportal-brustkrebs.de\/mercks-phase-3-study-shows-success-in-breast-cancer-treatment\/"},"modified":"2025-07-31T00:46:33","modified_gmt":"2025-07-30T22:46:33","slug":"mercks-phase-3-study-shows-success-in-breast-cancer-treatment","status":"publish","type":"post","link":"https:\/\/studienportal-brustkrebs.de\/en\/mercks-phase-3-study-shows-success-in-breast-cancer-treatment\/","title":{"rendered":"Merck&#8217;s Phase 3 Study Shows Success in Breast Cancer Treatment"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large is-style-default\"><img fetchpriority=\"high\" decoding=\"async\" width=\"700\" height=\"492\" src=\"https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01-700x492.jpg\" alt=\"\" class=\"wp-image-3875\" srcset=\"https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01-700x492.jpg 700w, https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01-300x211.jpg 300w, https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01-768x540.jpg 768w, https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01-624x439.jpg 624w, https:\/\/studienportal-brustkrebs.de\/wp-content\/uploads\/2024\/05\/Merck_KGaA_01.jpg 1280w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><figcaption class=\"wp-element-caption\">Photo: Armin K\u00fcbelbeck<\/figcaption><\/figure>\n<h2 class=\"wp-block-post-title\">Merck&#8217;s Phase 3 Study Shows Success in Breast Cancer Treatment<\/h2>\n<p>Merck announced that the Phase 3 KEYNOTE-522 study of Keytruda (anti-PD-1 therapy) met its overall survival endpoint in high-risk early-stage triple-negative breast cancer (TNBC). In combination with chemotherapy as a pre-operative treatment and subsequent monotherapy after surgery, Keytruda showed significant improvement compared to chemotherapy alone. No new safety concerns were identified. This is the first time an immunotherapy-based treatment has shown a survival benefit in TNBC patients.<\/p>\n\n<p><a href=\"https:\/\/www.pharmabiz.com\/ArticleDetails.aspx?aid=169398&amp;sid=2\" target=\"_blank\" rel=\"noopener\">More information&#8230;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck announced that the Phase 3 KEYNOTE-522 study of Keytruda (anti-PD-1 therapy) met its overall survival endpoint in high-risk early-stage triple-negative breast cancer (TNBC). In combination with chemotherapy as a pre-operative treatment and subsequent monotherapy after surgery, Keytruda showed significant improvement compared to chemotherapy alone. No new safety concerns were identified. This is the first [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":4781,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[52],"tags":[],"class_list":["post-4919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=4919"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4919\/revisions"}],"predecessor-version":[{"id":4920,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/posts\/4919\/revisions\/4920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/media\/4781"}],"wp:attachment":[{"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=4919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/categories?post=4919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-brustkrebs.de\/en\/wp-json\/wp\/v2\/tags?post=4919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}